Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

Official Title

An Open-label, Multicentre, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia

Summary:

The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).

Trial Description

Primary Outcome:

  • Frequency and Severity of Adverse Events (AEs), Laboratory Abnormalities, and Physical Exam Findings as a Measure of Safety
Secondary Outcome:
  • Serum Concentration of Cusatuzumab
  • Number of Participants with Anti-cusatuzumab Antibodies
  • Percentage of Participants with Complete Response (CR)
  • Percentage of Participants with Complete Remission with Partial Hematological Recovery (CRh)
  • Percentage of Participants with CR plus CRh
  • Percentage of Participants with CR with Incomplete Recovery (CRi)
  • Overall Response Rate (ORR)
  • Percentage of Participants with CR without MRD
  • Percentage of Participants with Negative MRD who Achieved CR, CRh, CRi, or Morphologic Leukemia-free State (MLFS)
  • Time to Response
  • Duration of Response
  • Red Blood Cell (RBC) or Platelet Transfusion Independence

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society